Understanding the order of genetic changes that lead to Wilms tumour to improve treatment
Ordering of driver mutations in bilateral Wilms’ tumour
Improving our understanding of how chemotherapy works in hepatoblastoma
Analysis of genome-wide 5-hydroxymethylcytosine patterns in human hepatoblastoma tumours during chemotherapy treatment
Helping to develop research into antibody treatment
Investigation of ganglioside-specific receptor expression by tumour-infiltrating immune cells
Discovering the differences between craniopharyngiomas that regrow after treatment and those that don't
Molecular profiling of relapsing craniopharyngioma
Improving our understanding of leukaemia that has spread throughout the body
Defining the tumour microenvironment in extramedullary acute leukaemia
Repurposing mebendazole and albendazole for acute myeloid leukaemia
Testing the use of mebendazole and albendazole for children with acute myeloid leukaemia, and investigating how the drugs work.
Improving treatment and reducing side effects for children with B-cell NHL
Identification of new drug targets to improve treatment options and reduce treatment-related toxicity for children diagnosed with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
Investigating a new way of delivery drugs to the site of childhood brain tumours
Brain distribution models to select polymer-delivered drugs for the treatment of childhood brain cancers
Developing a blood test to help identify high risk Wilms tumours
Circulating molecular biomarkers for earlier identification of high risk Wilms tumour